Answers are grounded in this paper and cite their sources.
This review examines safety profiles of facial biomaterials and implants, suggesting the need for regulatory compliance.
Facial esthetic procedures using biomaterials and implants for soft-tissue augmentation, contour enhancement, and rejuvenation have significantly increased, highlighting the need to understand their toxicological and safety profiles. This review examines the classification, biological behavior, and risks of commonly used materials, including natural fillers such as hyaluronic acid and synthetic implants such as silicone and polymethylmethacrylate. Although most demonstrate high biocompatibility, adverse reactions such as granuloma formation, fibrosis, delayed hypersensitivity, and rare systemic toxicities still occur. Advances in bioengineered and drug-eluting biomaterials show potential for reducing complications, yet long-term safety remains influenced by material properties, injection technique, and individual patient responses. A narrative review of peer-reviewed studies, clinical trials, and regulatory frameworks from 2000 to 2025 – sourced from PubMed, Scopus, and Web of Science – emphasizes that regulatory authorities such as the Food and Drug Administration, European Medicines Agency, and International Organization for Standardization provide critical standards for safety evaluation, while continuous postmarket surveillance is essential. Overall, facial esthetic biomaterials and implants are considered safe and effective when used appropriately, but sustained outcomes require meticulous procedural execution and regulatory compliance. Continued innovation and monitoring are imperative to optimize patient safety and long-term efficacy in esthetic practice.
No takes yet. Share an insight, caveat, or question.
Tyagi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: